MovDisordV3, Main, Exploration, bibRecord, 003D30

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease

Identifieur interne : 003D30 ( Main/Exploration ); précédent : 003D29; suivant : 003D31

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease

Auteurs : William Bara-Jimenez [États-Unis] ; Tzvetelina Dimitrova [États-Unis] ; Abdulah Sherzai [États-Unis] ; Antonella Favit [États-Unis] ; M. M. Mouradian [États-Unis] ; Thomas N. Chase [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2004-10.

RBID : ISTEX:57DC8D786BD5C8C8C3D4A4459736CDC316DC3006

English descriptors

KwdEn :
- Aged, Antiparkinson Agents (therapeutic use), Benzothiazoles, Carbidopa (therapeutic use), Dopamine Plasma Membrane Transport Proteins, Dopamine Uptake Inhibitors (therapeutic use), Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Humans, Indoles (therapeutic use), Levodopa (therapeutic use), Male, Membrane Glycoproteins, Membrane Transport Proteins, Middle Aged, Nerve Tissue Proteins, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson's disease, Pilot Projects, Thiazoles (therapeutic use), clinical trial, dopamine, dyskinesia, levodopa, striatum, transporter, uptake.
MESH :
- chemical , therapeutic use : Antiparkinson Agents, Carbidopa, Dopamine Uptake Inhibitors, Indoles, Levodopa, Thiazoles.
- diagnosis : Parkinson Disease.
- drug therapy : Parkinson Disease.
- Aged, Benzothiazoles, Dopamine Plasma Membrane Transport Proteins, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Humans, Male, Membrane Glycoproteins, Membrane Transport Proteins, Middle Aged, Nerve Tissue Proteins, Pilot Projects.

Abstract

Dopamine reuptake blockers, by enhancing and stabilizing intrasynaptic transmitter levels, could help palliate motor dysfunction in Parkinson's disease. This randomized, double‐blind, placebo‐controlled study compared the acute effects of the monoamine uptake inhibitor NS 2330 to those of placebo in 9 relatively advanced parkinsonian patients. At the dose administered, no change in parkinsonian scores was found when NS 2330 was given alone or with levodopa. Moreover, NS 2330 coadministration did not appear to alter dyskinesia severity or the duration of the antiparkinsonian response to levodopa. The drug was well tolerated. Under the conditions of this study, the present results failed to support the usefulness of dopamine reuptake inhibition in the treatment of advanced Parkinson's disease. © 2004 Movement Disorder Society

Url:

https://api.istex.fr/document/57DC8D786BD5C8C8C3D4A4459736CDC316DC3006/fulltext/pdf

DOI: 10.1002/mds.20124

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease</title>
<author><name sortKey="Bara Imenez, William" sort="Bara Imenez, William" uniqKey="Bara Imenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name>
</author>
<author><name sortKey="Dimitrova, Tzvetelina" sort="Dimitrova, Tzvetelina" uniqKey="Dimitrova T" first="Tzvetelina" last="Dimitrova">Tzvetelina Dimitrova</name>
</author>
<author><name sortKey="Sherzai, Abdulah" sort="Sherzai, Abdulah" uniqKey="Sherzai A" first="Abdulah" last="Sherzai">Abdulah Sherzai</name>
</author>
<author><name sortKey="Favit, Antonella" sort="Favit, Antonella" uniqKey="Favit A" first="Antonella" last="Favit">Antonella Favit</name>
</author>
<author><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:57DC8D786BD5C8C8C3D4A4459736CDC316DC3006</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1002/mds.20124</idno>
<idno type="url">https://api.istex.fr/document/57DC8D786BD5C8C8C3D4A4459736CDC316DC3006/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003155</idno>
<idno type="wicri:Area/Istex/Curation">003155</idno>
<idno type="wicri:Area/Istex/Checkpoint">002711</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Bara Imenez W:effect:of:monoamine</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15390018</idno>
<idno type="wicri:Area/PubMed/Corpus">003287</idno>
<idno type="wicri:Area/PubMed/Curation">003287</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003476</idno>
<idno type="wicri:Area/Ncbi/Merge">001001</idno>
<idno type="wicri:Area/Ncbi/Curation">001001</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001001</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Bara Jimenez W:effect:of:monoamine</idno>
<idno type="wicri:Area/Main/Merge">005688</idno>
<idno type="wicri:Area/Main/Curation">003D30</idno>
<idno type="wicri:Area/Main/Exploration">003D30</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease</title>
<author><name sortKey="Bara Imenez, William" sort="Bara Imenez, William" uniqKey="Bara Imenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dimitrova, Tzvetelina" sort="Dimitrova, Tzvetelina" uniqKey="Dimitrova T" first="Tzvetelina" last="Dimitrova">Tzvetelina Dimitrova</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sherzai, Abdulah" sort="Sherzai, Abdulah" uniqKey="Sherzai A" first="Abdulah" last="Sherzai">Abdulah Sherzai</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Favit, Antonella" sort="Favit, Antonella" uniqKey="Favit A" first="Antonella" last="Favit">Antonella Favit</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2004-10">2004-10</date>
<biblScope unit="vol">19</biblScope>
<biblScope unit="issue">10</biblScope>
<biblScope unit="page" from="1183">1183</biblScope>
<biblScope unit="page" to="1186">1186</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">57DC8D786BD5C8C8C3D4A4459736CDC316DC3006</idno>
<idno type="DOI">10.1002/mds.20124</idno>
<idno type="ArticleID">MDS20124</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Benzothiazoles</term>
<term>Carbidopa (therapeutic use)</term>
<term>Dopamine Plasma Membrane Transport Proteins</term>
<term>Dopamine Uptake Inhibitors (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Drug Combinations</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Indoles (therapeutic use)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Membrane Glycoproteins</term>
<term>Membrane Transport Proteins</term>
<term>Middle Aged</term>
<term>Nerve Tissue Proteins</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson's disease</term>
<term>Pilot Projects</term>
<term>Thiazoles (therapeutic use)</term>
<term>clinical trial</term>
<term>dopamine</term>
<term>dyskinesia</term>
<term>levodopa</term>
<term>striatum</term>
<term>transporter</term>
<term>uptake</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Carbidopa</term>
<term>Dopamine Uptake Inhibitors</term>
<term>Indoles</term>
<term>Levodopa</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Benzothiazoles</term>
<term>Dopamine Plasma Membrane Transport Proteins</term>
<term>Double-Blind Method</term>
<term>Drug Combinations</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Membrane Glycoproteins</term>
<term>Membrane Transport Proteins</term>
<term>Middle Aged</term>
<term>Nerve Tissue Proteins</term>
<term>Pilot Projects</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Dopamine reuptake blockers, by enhancing and stabilizing intrasynaptic transmitter levels, could help palliate motor dysfunction in Parkinson's disease. This randomized, double‐blind, placebo‐controlled study compared the acute effects of the monoamine uptake inhibitor NS 2330 to those of placebo in 9 relatively advanced parkinsonian patients. At the dose administered, no change in parkinsonian scores was found when NS 2330 was given alone or with levodopa. Moreover, NS 2330 coadministration did not appear to alter dyskinesia severity or the duration of the antiparkinsonian response to levodopa. The drug was well tolerated. Under the conditions of this study, the present results failed to support the usefulness of dopamine reuptake inhibition in the treatment of advanced Parkinson's disease. © 2004 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Bara Imenez, William" sort="Bara Imenez, William" uniqKey="Bara Imenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name>
</region>
<name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<name sortKey="Dimitrova, Tzvetelina" sort="Dimitrova, Tzvetelina" uniqKey="Dimitrova T" first="Tzvetelina" last="Dimitrova">Tzvetelina Dimitrova</name>
<name sortKey="Favit, Antonella" sort="Favit, Antonella" uniqKey="Favit A" first="Antonella" last="Favit">Antonella Favit</name>
<name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name>
<name sortKey="Sherzai, Abdulah" sort="Sherzai, Abdulah" uniqKey="Sherzai A" first="Abdulah" last="Sherzai">Abdulah Sherzai</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003D30 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003D30 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:57DC8D786BD5C8C8C3D4A4459736CDC316DC3006
   |texte=   Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.